A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke.

Jin Soo Lee, Ji Man Hong, Gyeong Joon Moon, Phil Hyu Lee, Young Hwan Ahn, Oh Young Bang, collaborators STARTING collaborators

Research output: Contribution to journalArticle

475 Citations (Scopus)

Abstract

We previously evaluated the short-term follow-up preliminary data of mesenchymal stem cells (MSCs) transplantation in patients with ischemic stroke. The present study was conducted to evaluate the long-term safety and efficacy of i.v. MSCs transplantation in a larger population. To accomplish this, we performed an open-label, observer-blinded clinical trial of 85 patients with severe middle cerebral artery territory infarct. Patients were randomly allocated to one of two groups, those who received i.v. autologous ex vivo cultured MSCs (MSC group) or those who did not (control group), and followed for up to 5 years. Mortality of any cause, long-term side effects, and new-onset comorbidities were monitored. Of the 52 patients who were finally included in this study, 16 were the MSC group and 36 were the control group. Four (25%) patients in the MSC group and 21 (58.3%) in the control group died during the follow-up period, and the cumulative surviving portion at 260 weeks was 0.72 in the MSC group and 0.34 in the control group (log-rank; p = .058). Significant side effects were not observed following MSC treatment. The occurrence of comorbidities including seizures and recurrent vascular episodes did not differ between groups. When compared with the control group, the follow-up modified Rankin Scale (mRS) score was decreased, whereas the number of patients with a mRS of 0-3 increased in the MSC group (p = .046). Clinical improvement in the MSC group was associated with serum levels of stromal cell-derived factor-1 and the degree of involvement of the subventricular region of the lateral ventricle. Intravenous autologous MSCs transplantation was safe for stroke patients during long-term follow-up. This therapy may improve recovery after stroke depending on the specific characteristics of the patients.

Original languageEnglish
Pages (from-to)1099-1106
Number of pages8
JournalStem cells (Dayton, Ohio)
Volume28
Issue number6
DOIs
Publication statusPublished - 2010 Jun

Fingerprint

Mesenchymal Stem Cell Transplantation
Mesenchymal Stromal Cells
Stroke
Control Groups
Comorbidity
Chemokine CXCL12
Lateral Ventricles
Middle Cerebral Artery
Blood Vessels
Seizures
Clinical Trials
Safety
Mortality

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

Lee, Jin Soo ; Hong, Ji Man ; Moon, Gyeong Joon ; Lee, Phil Hyu ; Ahn, Young Hwan ; Bang, Oh Young ; STARTING collaborators, collaborators. / A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. In: Stem cells (Dayton, Ohio). 2010 ; Vol. 28, No. 6. pp. 1099-1106.
@article{75477bdd4f04401bb492012eaaa4136f,
title = "A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke.",
abstract = "We previously evaluated the short-term follow-up preliminary data of mesenchymal stem cells (MSCs) transplantation in patients with ischemic stroke. The present study was conducted to evaluate the long-term safety and efficacy of i.v. MSCs transplantation in a larger population. To accomplish this, we performed an open-label, observer-blinded clinical trial of 85 patients with severe middle cerebral artery territory infarct. Patients were randomly allocated to one of two groups, those who received i.v. autologous ex vivo cultured MSCs (MSC group) or those who did not (control group), and followed for up to 5 years. Mortality of any cause, long-term side effects, and new-onset comorbidities were monitored. Of the 52 patients who were finally included in this study, 16 were the MSC group and 36 were the control group. Four (25{\%}) patients in the MSC group and 21 (58.3{\%}) in the control group died during the follow-up period, and the cumulative surviving portion at 260 weeks was 0.72 in the MSC group and 0.34 in the control group (log-rank; p = .058). Significant side effects were not observed following MSC treatment. The occurrence of comorbidities including seizures and recurrent vascular episodes did not differ between groups. When compared with the control group, the follow-up modified Rankin Scale (mRS) score was decreased, whereas the number of patients with a mRS of 0-3 increased in the MSC group (p = .046). Clinical improvement in the MSC group was associated with serum levels of stromal cell-derived factor-1 and the degree of involvement of the subventricular region of the lateral ventricle. Intravenous autologous MSCs transplantation was safe for stroke patients during long-term follow-up. This therapy may improve recovery after stroke depending on the specific characteristics of the patients.",
author = "Lee, {Jin Soo} and Hong, {Ji Man} and Moon, {Gyeong Joon} and Lee, {Phil Hyu} and Ahn, {Young Hwan} and Bang, {Oh Young} and {STARTING collaborators}, collaborators",
year = "2010",
month = "6",
doi = "10.1002/stem.430",
language = "English",
volume = "28",
pages = "1099--1106",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "6",

}

A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. / Lee, Jin Soo; Hong, Ji Man; Moon, Gyeong Joon; Lee, Phil Hyu; Ahn, Young Hwan; Bang, Oh Young; STARTING collaborators, collaborators.

In: Stem cells (Dayton, Ohio), Vol. 28, No. 6, 06.2010, p. 1099-1106.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke.

AU - Lee, Jin Soo

AU - Hong, Ji Man

AU - Moon, Gyeong Joon

AU - Lee, Phil Hyu

AU - Ahn, Young Hwan

AU - Bang, Oh Young

AU - STARTING collaborators, collaborators

PY - 2010/6

Y1 - 2010/6

N2 - We previously evaluated the short-term follow-up preliminary data of mesenchymal stem cells (MSCs) transplantation in patients with ischemic stroke. The present study was conducted to evaluate the long-term safety and efficacy of i.v. MSCs transplantation in a larger population. To accomplish this, we performed an open-label, observer-blinded clinical trial of 85 patients with severe middle cerebral artery territory infarct. Patients were randomly allocated to one of two groups, those who received i.v. autologous ex vivo cultured MSCs (MSC group) or those who did not (control group), and followed for up to 5 years. Mortality of any cause, long-term side effects, and new-onset comorbidities were monitored. Of the 52 patients who were finally included in this study, 16 were the MSC group and 36 were the control group. Four (25%) patients in the MSC group and 21 (58.3%) in the control group died during the follow-up period, and the cumulative surviving portion at 260 weeks was 0.72 in the MSC group and 0.34 in the control group (log-rank; p = .058). Significant side effects were not observed following MSC treatment. The occurrence of comorbidities including seizures and recurrent vascular episodes did not differ between groups. When compared with the control group, the follow-up modified Rankin Scale (mRS) score was decreased, whereas the number of patients with a mRS of 0-3 increased in the MSC group (p = .046). Clinical improvement in the MSC group was associated with serum levels of stromal cell-derived factor-1 and the degree of involvement of the subventricular region of the lateral ventricle. Intravenous autologous MSCs transplantation was safe for stroke patients during long-term follow-up. This therapy may improve recovery after stroke depending on the specific characteristics of the patients.

AB - We previously evaluated the short-term follow-up preliminary data of mesenchymal stem cells (MSCs) transplantation in patients with ischemic stroke. The present study was conducted to evaluate the long-term safety and efficacy of i.v. MSCs transplantation in a larger population. To accomplish this, we performed an open-label, observer-blinded clinical trial of 85 patients with severe middle cerebral artery territory infarct. Patients were randomly allocated to one of two groups, those who received i.v. autologous ex vivo cultured MSCs (MSC group) or those who did not (control group), and followed for up to 5 years. Mortality of any cause, long-term side effects, and new-onset comorbidities were monitored. Of the 52 patients who were finally included in this study, 16 were the MSC group and 36 were the control group. Four (25%) patients in the MSC group and 21 (58.3%) in the control group died during the follow-up period, and the cumulative surviving portion at 260 weeks was 0.72 in the MSC group and 0.34 in the control group (log-rank; p = .058). Significant side effects were not observed following MSC treatment. The occurrence of comorbidities including seizures and recurrent vascular episodes did not differ between groups. When compared with the control group, the follow-up modified Rankin Scale (mRS) score was decreased, whereas the number of patients with a mRS of 0-3 increased in the MSC group (p = .046). Clinical improvement in the MSC group was associated with serum levels of stromal cell-derived factor-1 and the degree of involvement of the subventricular region of the lateral ventricle. Intravenous autologous MSCs transplantation was safe for stroke patients during long-term follow-up. This therapy may improve recovery after stroke depending on the specific characteristics of the patients.

UR - http://www.scopus.com/inward/record.url?scp=77956638921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956638921&partnerID=8YFLogxK

U2 - 10.1002/stem.430

DO - 10.1002/stem.430

M3 - Article

C2 - 20506226

AN - SCOPUS:77956638921

VL - 28

SP - 1099

EP - 1106

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 6

ER -